Bicycle Therapeutics Stock Investor Sentiment

BCYC Stock  USD 20.40  0.05  0.25%   
About 56% of Bicycle Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Bicycle Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Bicycle Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Bicycle Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Bicycle Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Bicycle Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at finance.yahoo.com         
Bicycle Therapeutics Announces 555 Million Private Placement Equity Financing
Yahoo News
over six months ago at businesswire.com         
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase...
businesswire News
over six months ago at finance.yahoo.com         
Is Bicycle Therapeutics Outperforming Other Medical Stocks This Year?
Yahoo News
over six months ago at zacks.com         
Is Bicycle Therapeutics Outperforming Other Medical Stocks This Year?
zacks News
over six months ago at news.google.com         
Bicycle Therapeutics PLC Sponsored ADR Surges 9.0 percent Is This an Indication of Further Gains - Y...
Google News at Macroaxis
over six months ago at news.google.com         
Jump Financial LLC Purchases 40,265 Shares of Bicycle Therapeutics plc - MarketBeat
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Bourque Janice of 6000 shares of Bicycle Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at simplywall.st         
Shareholders May Not Be So Generous With Bicycle Therapeutics plcs CEO Compensation And Heres Why
Simply Wall St News at Macroaxis
over six months ago at simplywall.st         
Acquisition by Arroyo Santiago of 17340 shares of Bicycle Therapeutics subject to Rule 16b-3
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Trading Advice - Stock Traders Daily
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Upgrade Analysts Just Made A Massive Increase To Their Bicycle Therapeutics plc Forecasts
Yahoo News
over six months ago at finance.yahoo.com         
Wall Street Analysts See a 77.22 percent Upside in Bicycle Therapeutics Can the Stock Really Move Th...
Yahoo News
over six months ago at zacks.com         
Bicycle Therapeutics Moves to Buy Rationale Behind the Upgrade
zacks News
over six months ago at zacks.com         
Wall Street Analysts See a 77.22 percent Upside in Bicycle Therapeutics Can the Stock Really Move Th...
zacks News
over six months ago at simplywall.st         
Analysts Revenue Estimates For Bicycle Therapeutics plc Are Surging Higher
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Bicycle Therapeutics that are available to investors today. That information is available publicly through Bicycle media outlets and privately through word of mouth or via Bicycle internal channels. However, regardless of the origin, that massive amount of Bicycle data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bicycle Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bicycle Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bicycle Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bicycle Therapeutics alpha.

Bicycle Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
10/02/2024
2
Disposition of 153 shares by Travis Thompson of Bicycle Therapeutics at 22.26 subject to Rule 16b-3
10/03/2024
3
Acquisition by Nicholas Keen of 28000 shares of Bicycle Therapeutics subject to Rule 16b-3
10/04/2024
4
Bicycle Therapeutics plc Short Interest Up 12.3 percent in September
10/16/2024
5
Bicycle Therapeutics plc Announces Positive Human Imaging Data at EANM 2024 Congress and Radiopharmaceutical Strategy
10/23/2024
6
Bicycle Therapeutics Buy Rating Reiterated at Needham Company LLC
10/25/2024
7
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
10/31/2024
8
Bicycle Therapeutics Looking Again At An Intriguing Developmental Concern - Seeking Alpha
11/07/2024
9
Disposition of 154 shares by Travis Thompson of Bicycle Therapeutics at 8.21 subject to Rule 16b-3
11/11/2024
10
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
11/12/2024
11
Principal Financial Group Inc. Makes New Investment in Bicycle Therapeutics plc - MarketBeat
11/19/2024
12
Disposition of 1109 shares by Travis Thompson of Bicycle Therapeutics at 9.82 subject to Rule 16b-3
11/20/2024
13
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
11/25/2024

Complementary Tools for Bicycle Stock analysis

When running Bicycle Therapeutics' price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance